| 证券代码 | SHPH.O |
| 证券名称 | Shuttle Pharmaceuticals Holdings Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2022-08-31 |
| 首发价格(元) | 8.125 USD |
| 首发数量(股) | 1225888 |
| 首发募资额(元) | 9,960,340.00 USD |
| 首发主承销商 | Boustead Securities, LLC |
| 货币单位 | USD |
| 公司名称 | Shuttle Pharmaceuticals Holdings, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | One Research Court, Suite 450, Rockville, Maryland, USA |
| 成立日期 | 2012 |
| 董事会主席 | Anatoly Dritschilo |
| 公司属地 | United States 美国 |
| 公司网址 | www.shuttlepharma.com |
| 电话 | +1 (240) 403-4212 |
| 传真 | - |
| 公司简介 | Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company leveraging their proprietary technology to develop novel therapies that are designed to cure cancer. Their goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy. While there are several therapies being developed with the goal of curing cancer, one of the most effective and proven approaches to this is radiation therapy (RT). The Company has developed technology that operates in three distinct areas related to the treatment of cancer with radiation therapy: 1. sensitization of growing cancer cells, rendering them susceptible to the effects of radiation therapy, 2. sensitization of hypoxic cells in tumors that resist radiation therapy, and 3. activation of the DNA damage response pathway to kill cancer cells and protect normal cells located near cancers, this technology effects the immune response and has the potential to integrate with checkpoint inhibitors and immune therapies. |